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Randomised controlled trial of an interactive multimedia
decision aid on hormone replacement therapy in
primary care
Elizabeth Murray, Hilary Davis, Sharon See Tai, Angela Coulter, Alastair Gray, Andy Haines
Abstract
Objective To determine whether a decision aid on
hormone replacement therapy influences decision
making and health outcomes.
Design Randomised controlled trial.
Setting 26 general practices in the United Kingdom.
Participants 205 women considering hormone
replacement therapy.
Intervention Patients’ decision aid consisting of an
interactive multimedia programme with booklet and
printed summary.
Outcome measures Patients’ and general
practitioners’ perceptions of who made the decision,
decisional conflict, treatment choice, menopausal
symptoms, costs, anxiety, and general health status.
Results Both patients and general practitioners found
the decision aid acceptable. At three months, mean
scores for decisional conflict were significantly lower
in the intervention group than in the control group
(2.5 v 2.8; mean difference − 0.3, 95% confidence
interval − 0.5 to − 0.2); this difference was maintained
during follow up. A higher proportion of general
practitioners perceived that treatment decisions had
been made “mainly or only” by the patient in the
intervention group than in the control group (55% v
31%; 24%, 8% to 40%). At three months a lower
proportion of women in the intervention group than
in the control group were undecided about treatment
(14% v 26%; − 12%, − 23% to − 0.4%), and a higher
proportion had decided against hormone
replacement therapy (46% v 32%; 14%, 1% to 28%);
these differences were no longer apparent by nine
months. No differences were found between the
groups for anxiety, use of health service resources,
general health status, or utility. The higher costs of the
intervention were largely due to the video disc
technology used.
Conclusions An interactive multimedia decision aid
in the NHS would be popular with patients, reduce
decisional conflict, and let patients play a more active
part in decision making without increasing anxiety.
The use of web based technology would reduce the
cost of the intervention.
Introduction
Decision aids to assist patients in deciding about health
care have been welcomed as one solution for
improving doctor›patient communication, providing
information for patients, and addressing the shortcom›
ings in much of the information available.1–5 Both
patient outcomes and the rational use of health service
resources may be improved by better provision of
information.6–9
Decision aids for patients differ from simple infor›
mation packages. As well as containing information
about the probability of risks and benefits of available
treatments, they often contain exercises to help
patients clarify their own health needs, and they
emphasise that different patients reach different
decisions.10 Decision aids aim to promote shared deci›
sion making,11 where the clinician and patient jointly
negotiate and agree on a treatment decision, taking
into account both the probability of a range of clinical
outcomes and the relative weight the patient places on
these outcomes.
A recent systematic review of decision aids
determined that they improve patients’ knowledge of
their condition and treatment options.12 They seem to
help with decision making in that “decisional conflict
scores” (a measure of patients’ internal perceptions of
ability to make a decision and satisfaction with the
decision made) tend to be lower in groups that have
used a decision aid than in control groups.13 There are,
however, several unanswered questions,14 in particular
the impact of decision aids on choice of treatment, sat›
isfaction, health status, and persistence with treatment.
Additionally, as most trials have been done in second›
ary care in the United States, there is little evidence on
the use of decision aids in primary care. Few data are
also available on clinicians’ perceptions of decision aids
or their cost effectiveness. We address these questions
here and in the accompanying paper on patients with
benign prostatic hypertrophy.15 The two trials were
designed to complement each other by examining
qualitatively different decisions in different populations
(table 1). In this paper we aimed to determine whether
an interactive multimedia decision aid promoted
greater patient involvement in decision making and
what influence this had on the uptake of hormone
replacement therapy, health status, and anxiety. We also
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aimed to determine the acceptability of such a system
to patients and general practitioners and the impact on
a general practitioner’s workload and to undertake an
economic analysis.
Participants and methods
Patient recruitment
We invited general practitioners in two urban (Oxford
and London) areas and one suburban (Harrow) and
one semirural (Thame and the Chilterns) area to
participate in our study. We asked participating general
practitioners to recruit perimenopausal or menopau›
sal women who were facing a decision about whether
to start, stop, or continue with hormone replacement
therapy. The women needed a sufficient understanding
of English to be able to consult without an interpreter.
Women were excluded if there was an absolute indica›
tion or contraindication to hormone replacement
therapy or if they had breast or pelvic cancer, severe
visual or hearing impairment, or severe learning
difficulties or mental illness. Ethical approval was
obtained from local research ethics committees.
Intervention
The intervention, developed by the Foundation for
Informed Medical Decision Making, comprised an
interactive multimedia programme, with booklet and
printed summary.16 Information comprised quantified
probabilities of the risks and benefits of hormone
replacement therapy taken from systematic reviews
and other published data available in 1996 and
updated in 1998. Topics discussed were menopausal
symptoms, mood changes, skin changes, changes in
energy, vaginal dryness, changes in libido, heart
disease, osteoporosis, breast cancer, and endometrial
cancer. After viewing the programme the patients were
given a summary of the information; a copy was also
sent to their general practitioners.
As the programme used interactive video disc tech›
nology, we imported specialised hardware from the
United States. This limited the number of machines
available for patients to use. Patients travelled to one of
five sites, chosen for ease of access from referring prac›
tices, to view the programme in a private room. All the
patients saw the core programme, lasting about one
hour; viewing optional sections for further information
took up to 30 minutes more.
Randomisation
Patients randomised to the control group received
normal clinical care. Randomisation was performed
after obtaining informed consent and baseline data
from eligible patients. The randomisation schedule,
stratified according to recruitment centre, was gener›
ated by computer. Allocations were sealed in opaque
numbered envelopes, opened by the study nurse after
collection of the baseline data.
Data collection
We collected data from the patients at baseline and at
three and nine months after randomisation. Outcome
measures included personal details, decisional conflict
scores, patients’ and general practitioners’ perceptions
of who made the decision, treatment preference,
persistence with treatment, anxiety (Spielberger state
trait anxiety inventory short form),17 health status and
limitations in physical functioning (SF›36),18 health
states and valuation of health states (EQ›5D),19 and
menopausal symptoms (MenQol).20 Patients in the
intervention group completed a questionnaire imme›
diately after viewing the programme.
After the follow up consultation the general practi›
tioners filled in a questionnaire to determine the time
spent on the consultation, their perceptions of who
made the treatment decision, and whether the
programme had helped or hindered the consultation
for patients in the intervention group.
Economic evaluation
We recorded the resources used by each patient over
the trial period. These were the cost of providing the
interactive information (video costs, nurse time, and
accommodation were shared with the accompanying
trial, with 64% of costs attributed to the present study
on the basis of patient numbers), the number and
duration of consultations with the general practitioner,
the number of referrals to specialists, and the use of
hormone replacement therapy and related drugs. The
unit costs were attached to resource volumes to obtain
a total cost per patient. As the technology we used was
superseded by CD Rom, personal computer, and inter›
net technology by the time our trial was completed, we
also present some estimates of the costs of an alterna›
tive delivery system. Utility was measured with the
EQ›5D at baseline and at three and nine months. Valu›
ations of health states were taken from the UK popula›
tion tariff.21 We compared point values, summed values
over the trial, and changes from baseline to the end of
the trial. We conducted our economic evaluation from
the perspective of the healthcare system. All costs are
in pounds sterling at 1999 prices. To aid generalisabil›
ity of the results we obtained unit costs from national
sources where possible (table 2).
Sample size
Evidence has shown that the more information women
have about hormone replacement therapy, the greater
is the likelihood of their using it.22 We therefore
hypothesised that more women in the intervention
group than in the control group would choose
hormone replacement therapy. Allowing for a 30%
dropout rate, 120 women in each arm (84 women
Table 1 Details of two studies on decision aids
Characteristic Benign prostatic hypertrophy study Hormone replacement therapy study
Decision type Irreversible after surgery: “rubicon”
decision
Reversible
Benefits Immediate Immediate and delayed
Risks Immediate Largely delayed
Sex of participants Men Women
Age of participants Mostly >60 Mostly >50
Eligible population Subsection (symptomatic men) Potentially all menopausal women
Table 2 Unit costs in pounds sterling (at 1999 prices) and sources of information used
in economic evaluation
Item Unit cost Source
Generic consultation with doctor 14.00 Department of Health
Doctor’s cost per minute (initial intervention) 1.62 Department of Health
3 months’ supply of Prempak›C 15.00 British National Formulary
Specialist referral from doctor 60.00 Department of Health TFR2 returns
Interactive session* 216.06
*Total equipment costs £17 520. Software cost $1300 (£770) per disc; total cost $6500 (£3850) plus £400
for shipping and insurance. Mean cost per patient £216.
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completing the trial) would give our study an 80%
power of detecting a 15% point difference in use of
hormone replacement therapy (between 8% and
23%)23 in the two arms at the 5% significance level. A
retrospective calculation showed that the power of our
actual sample size to determine the observed
difference in decisional conflict score between the two
groups at the final assessment was 95% at the 5%
significance level.
Statistical analysis
We analysed data for all outcomes for those patients
who completed all the assessments. We also performed
an intention to treat analysis to allow for those patients
who did not complete the study and who were
therefore unable to provide data at the nine months’
assessment. For that analysis we assumed no change in
score on any outcome from the beginning of the study,
and we substituted baseline data for the missing data at
the final assessment. We present the results for those
who completed the nine months’ assessment, as the
intention to treat analysis did not alter the results.
We compared the change in scores from baseline
to final assessment for the MenQol and Spielberger
scales between study groups, and we compared
decisional conflict scores between the two groups at
three and nine months. We present the means and
standard deviations for resource use and costs and
means and 95% confidence intervals for differences in
resource use and costs by allocation.
Results
Recruitment
Overall, 26 general practices agreed to participate; 12
from London and Harrow, 14 from Oxford and
Thame and the Chilterns. Between October 1996 and
August 1998, 205 women were recruited (figure).
Baseline characteristics
The intervention and control groups were comparable
at baseline (table 3) except for educational achieve›
ment, which was higher in the control group.
Subsequent analysis showed that educational attain›
ment was not related to use of hormone replacement
therapy nor was there an interaction between
educational attainment and the intervention.
Reactions to decision aid
Patients reacted positively to the decision aid (table 4).
Women in the intervention group seemed to make a
more definite choice about treatment than those in the
control group, with fewer women being “undecided”
and more women deciding not to take hormone
replacement therapy at three months; by nine months,
however, this difference was no longer significant (table
5). This was confirmed by the decisional conflict scores,
which were lower in the intervention group than in the
control group at three months (table 6); the significant
differences persisted at nine months (total score at nine
months: mean (SD) scores, intervention group 2.45
(0.56), control group 2.80 (0.61); mean difference
Patients referred to study by general practitioner (n=259)
Randomised (n=205)
Intervention
Received intervention as allocated (n=102)
Did not receive intervention as allocated (n=1);
patient dropped out of trial after randomisation
Not contactable (n=14)
Control
Received intervention as allocated (n=102)
Followed up at 3 months (n=94);
4 women who did not complete data at
3 months did at 9 months
Followed up at 9 months (n=93)
Followed up at 3 months (n=96);
3 women who did not complete data at
3 months did at 9 months
Followed up at 9 months (n=94)
Completed trial (n=93) Completed trial (n=94)
Dropped out (n=8)Dropped out (n=10)
Not randomised (n=40):
 Ill health in family (n=2)
 Too busy (n=9)
 Misunderstood purpose of study (n=2)
 Difficult relation with general
   practitioner (n=1)
 No menopausal symptoms (n=1)
 Had made decision (n=2)
 Could obtain information elsewhere (n=2)
 No reason (n=13)
 Did not attend appointment (n=7)
 Unknown (n=1)
Progress of patients through trial
Table 4 Acceptability of decision aid to patients
No (%) of patients (n=101)
Was the video easy to understand?
Very easy 84 (82)
Quite easy 17 (17)
Quite difficult 0
Very difficult 0
Effect on understanding of issues around hormone replacement therapy
Understand more 88 (87)
Understand same 13 (13)
Understand less 0
Effect on difficulty of decision making
Easier to decide 56 (54)
Neither easier nor harder to decide 37 (36)
Harder to decide 8 (8)
Table 3 Baseline characteristics of participants. Values are numbers (percentages) of
women unless stated otherwise
Characteristic
Intervention group
(n=103)
Control group
(n=102)
Mean age (years) 50.75 50.11
Ethnicity (white) 95 (92) 93 (93)
Educational attainment:
Up to secondary education 40 (39) 24 (24)
Beyond secondary education 63 (61) 78 (77)
Treatment choice for hormone replacement therapy:
To take 31 (30) 27 (27)
Not to take 21 (20) 18 (18)
Let doctor decide 4 (4) 5 (5)
Unsure 47 (46) 51 (51)
Mean (SD) MenQol score:
Vasomotor 2.71 (1.73) 3.02 (2.0)
Psychosocial 3.55 (1.82) 3.65 (1.81)
Physical 3.42 (1.33) 3.47 (1.35)
Sexual 2.85 (2.16) 2.34 (1.62)
Mean (SD) decisional conflict score:
Uncertainty 3.61 (0.73) 3.69 (0.87)
Factors contributing to uncertainty 2.70 (0.45) 2.65 (0.46)
Mean (SD) score on Spielberger state trait anxiety inventory 38.87 (12.34) 38.73 (13.18)
Papers
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− 0.35, 95% confidence interval for mean difference
− 0.53 to − 0.16). General practitioners perceived the
decision to have been made “mainly or only [by the]
patient” in a significantly higher proportion of patients
in the intervention group than in the control group,
although there were no differences in patients’ percep›
tions of who should make the decision (table 7). The
wording of the question was altered from “who made
the treatment decision” (asked in the study on benign
prostatic hypertrophy) to “who do you think should
make the treatment decision?” as we postulated that
many women would not have made a decision about
their treatment by the end of the trial.
We found no significant difference between the two
groups in the change in anxiety score between baseline
and at nine months (t test, mean change scores:
intervention group 0.34, control group 2.49, mean dif›
ference − 2.15, − 6.45 to 2.16). We also found no
significant changes in scores from baseline to final
assessment between the two groups in the SF›36 or the
EQ›5D or MenQol.
Of 73 subsequent consultations, the general practi›
tioners said that the decision aid helped in 61 (84%),
made no difference in 11, and hindered one.
Economic analysis
Table 8 shows the resources used and the costs per
patient by allocation group. No significant differences
were detected when the cost of the trial technology was
excluded. When the cost of the video intervention was
included, the cost per patient was £306 in the interven›
tion group and £91 in the control group over nine
months (P < 0.001).
Discussion
Our pair of trials are the first randomised controlled
trials of interactive multimedia decision aids in a
primary care population in the United Kingdom. The
decision aid in this paper was acceptable to both the
patients and their general practitioners. It enhanced
the women’s understanding of the effects of hormone
replacement therapy and seemed to reduce decisional
conflict for the duration of follow up. Lower decisional
conflict scores imply less uncertainty about the
decision. At three months fewer women in the
intervention group than in the control group were
undecided about their use of hormone replacement
therapy. The general practitioners perceived a higher
proportion of patients in the intervention group than
in the control group to have “mainly or only” made the
decision, although this finding must be interpreted
with caution as the doctors were not blinded to the
patients’ study groups. The intervention made no
difference to the rate of uptake of hormone
replacement therapy or the use of health service
resources in general. The main costs of the
intervention were due to the technology used. These
findings are compatible with the recent systematic
review of decision aids5 and provide new information
on the acceptability of such decision aids to clinicians
and patients in primary care and the impact on costs to
the NHS.
Implications for the NHS
Public demand for improved access to quality sources
of information is high and likely to increase. Decision
aids have the potential to alter the use of healthcare
resources in line with patients’ preferences and,
through the influence of patient choice on clinicians,
may help to promote evidence based practice.24 No
study has yet examined the effect of decision aids on
Table 5 Treatment preferences for hormone replacement therapy at three and nine
months’ follow up. Values are numbers (percentages) of patients unless stated otherwise
Treatment preference Intervention group Control group % difference (95% CI)
Three months’ follow up*:
Therapy 36 (40) 40 (42) −2.1 (−16.3 to 12.1)
No therapy 41 (46) 30 (32) 14 (0.8 to 27.9)
Undecided 13 (14) 25 (26) −11.9 (−23.3 to −0.4)
Nine months’ follow up†:
Therapy 36 (41) 31 (36) 5.8 (−8.7 to 20.2)
No therapy 46 (53) 44 (51) 2.3 (−12.5 to 17.1)
Undecided 5 (6) 12 (14) −8.1 (−16.8 to 0.7)
Data are missing for some participants.
Confidence intervals are based on t tests assuming unequal variances between study groups.
*÷2=5.573, df=2, P=0.06.
†÷2=3.30, df=2, P=0.2.
Table 6 Decisional conflict scores at three months. Values are means (SDs) unless
stated otherwise
Intervention
group Control group Mean difference (95% CI)
Uncertainty 3.1 (1.0) 3.4 (1.1) −0.3 (−0.7 to −0.04)*
Factors contributing to uncertainty 2.4 (0.5) 2.8 (0.6) −0.4 (−0.5 to −0.2)**
Perceived effective decision making 2.2 (0.6) 2.5 (0.7) −0.3 (−0.5 to −0.2)**
Total decisional conflict score 2.5 (0.5) 2.8 (0.6) −0.3 (−0.5 to −0.2)**
*P<0.05. **P<0.01.
The decisional conflict scale contains three subscales that elicit uncertainty about choosing between
alternatives, awareness of modifiable factors contributing to uncertainty, and perceived effectiveness of
decision making process. Higher scores indicate increased uncertainty in each subscale. Subscales can be
combined to give a total decisional conflict score.
Table 7 Patients’ and general practitioners’ perceptions of decision making. Values are
numbers (percentages) of patients unless stated otherwise
Intervention group Control group % difference (95% CI)
General practitioners (n=76) (n=67)
Who do you think made the treatment decision?:
Mainly or only general practitioner 1 (1.3) 2 (3) −1.7 (−6.5 to 3.1)
General practitioner and patient together 33 (43.4) 44 (65.7) −22.3 (−38.2 to −6.3)
Mainly or only patient 42 (55.3) 21 (31.3) 24 (8.2 to 39.7)*
÷2=8.37, df=2, P=0.015
Patients (n=94) (n=95)
Who do you think should make the treatment decision?:
Mainly or only general practitioner 5 (5.3) 6 (6.3) −1.0 (−7.7 to 5.7)
Patient and general practitioner together 40 (42.6) 36 (37.9) 4.7 (−9.3 to 18.6)
Mainly or only patient 49 (52.1) 53 (55.8) −3.7 (−17.9 to 10.5)
÷2=0.45, df=2, P=0.8
Table 8 Resource use and costs in sterling (at 1999 prices) per patient, by allocation.
Values are means (SDs) unless stated otherwise
Intervention
(n=85)
Control
(n=84)
Mean difference
(95% CI)
Cost of video technology 216.00 0 216
Duration of initial consultation (minutes) 13.4 (5.9) 13.9 (5.8) −0.5 (−2.5 to 1.6)
No of appointments to see doctor over
9 months
3.4 (1.2) 3.6 (1.5) −0.2 (−0.6 to 0.2)
Cost of appointments over 9 months 64.6 (23.6) 66.5 (24.6) −1.9 (−9.2 to 5.5)
No of specialist referrals over 9 months 0.03 (0.17) 0.03 (0.18) 0.00 (−0.06 to 0.06)
Cost of specialist referrals over 9 months 1.7 (10.1) 1.9 (10.6) −0.19 (−3.75 to 3.37)
Cost of hormone replacement therapy over
9 months
24.3 (28.3) 23.0 (27.2) 1.3 (−7.1 to 9.7)
Total cost 306.5 (42.8) 90.9 (39.2) 215.5 (203.1 to 228.0)***
***P<0.001.
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litigation, although viewing such a programme could
be considered evidence of informed consent.
Delivering programmes to standard personal com›
puters through the internet would reduce the cost per
session from about £177 to £5 (excluding the cost of
software). This assumes equipment costs of £1500 over
three years, with a fairly low utilisation rate (two users
per weekday) and lower space and staff costs commen›
surate with a less dedicated technology. Thus this type
of interactive decision aid, which provides a realistic
and practical solution to the problem of achieving
informed patient choice at low cost, could easily be
incorporated into multiple access points for infor›
mation such as those envisaged for NHS Direct Online.
Our trial was not designed to determine the extent to
which patients would seek out and use a decision aid if
they were not referred to it; however the rapid rise in
numbers of visitors to health information sites on the
internet25 confirms previous evidence on the wide›
spread demand by patients for information on health
care.
Conclusions
Evidence shows that further coordinated investment is
required in decision aids for patients. This would
involve incorporation of information from systematic
reviews (where available) into high quality decision
aids, particularly addressing decisions where patients’
needs are paramount.
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What is already known on this topic
Patients want more information about their
conditions and treatment options, and many want
to play an active part in decision making
Decision aids improve patients’ knowledge of their
conditions and treatment options
What this study adds
The decision aid was acceptable to both the
patients and their general practitioners
Decisional conflict was reduced in the intervention
group
Patients who viewed the programme played a
more active part in the decision making process
and were no more anxious than control patients
Such aids could be introduced throughout the
NHS at relatively low cost by using the internet
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